KALV — Kalvista Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $854.74m
- $817.60m
Annual cashflow statement for Kalvista Pharmaceuticals, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -46.2 | -82.3 | -92.9 | -127 | -183 |
| Depreciation | |||||
| Non-Cash Items | 7.19 | 16 | 9.52 | 21.4 | 14.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.35 | -12.3 | 7.41 | 15.2 | 15 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.2 | -78.1 | -75.3 | -89.2 | -153 |
| Capital Expenditures | -0.082 | -0.931 | -1.2 | -0.443 | -0.929 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | -148 | 58.8 | 42.6 | -84.3 | 92 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -148 | 57.9 | 41.4 | -84.7 | 91 |
| Financing Cash Flow Items | — | — | — | — | -1.96 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 212 | 1.58 | 58.1 | 151 | 160 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 34.8 | -19.9 | 25.5 | -24.4 | 100 |